Moat
84.0/10
Prescription veterinary medicines, approved parasiticides, dermatology franchises, global distribution, veterinarian trust, regulatory compliance, and recurring companion-animal demand create strong switching and trust barriers.
ZTSQueued from the May 25, 2026 S&P 500 market-cap snapshot ranks 251-275; rankApprox uses the cohort midpoint because the manifest did not include an exact rank.
Zoetis
Zoetis develops and sells medicines, vaccines, diagnostics, and related services for companion animals and livestock.
Metadata
Where this company sits
- Ticker
- ZTS
- Rank snapshot
- ≈ 263
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Region
- United States
- Index
- S&P 500 · Top 275 by market cap
Metrics
Scoring view
Every metric is paired with a short rationale. The numbers are deliberate, not divine.
Decentralizability
25.0/10
Approved veterinary drugs are hard to decentralize directly, but discovery tooling, outcome evidence, parasite surveillance, and clinic-owned coordination layers can be opened or federated.
Profitability
86.0/10
The 2025 Form 10-K reported $2.67 billion of GAAP net income attributable to Zoetis on $9.47 billion of revenue, implying a strong profit margin for an animal-health pharmaceutical platform.
Price / Earnings
12.5x
StockAnalysis reported a trailing P/E ratio of 12.46 for ZTS after the June 26, 2026 close.
Market cap
$31.9B
CompaniesMarketCap reported Zoetis's market capitalization at about $31.89 billion as of June 2026, with a June 26, 2026 end-of-day figure of $31.89 billion.
Freed-up capital potential
$0.0
Derived from market cap, moat resistance, decentralizability, and profitability. It is a directional estimate of value capture that could come under pressure if open alternatives compound.
Narrative
Why the company matters
A short editorial overview plus the current thesis on moat strength and decentralization pressure.
Business mix
Zoetis is a global animal-health company whose portfolio spans companion-animal and livestock medicines, vaccines, diagnostics, biopharmaceuticals, genetic tests, and digital tools.
The 2025 Form 10-K reported $9.47 billion of revenue, with companion-animal products generating $6.59 billion and product-category strength concentrated in parasiticides, vaccines, and dermatology.
Registry fit
Zoetis is a strong incumbent case because its leading products depend on prescription channels, veterinarian trust, regulatory approvals, clinical evidence, manufacturing quality, brand recognition, and large-scale distribution.
Free, open, or decentralized pressure is more credible around discovery tooling, comparative outcomes data, parasite surveillance, cooperative procurement, and post-exclusivity access than as a direct unsupervised replacement for approved veterinary drugs.
Moat reading
Zoetis has a high moat because animal medicines and vaccines are regulated products sold through trusted veterinary and producer channels. Its recurring companion-animal franchises, especially parasiticides and dermatology, benefit from clinical familiarity, pet-owner demand, prescription workflows, safety monitoring, and global commercial reach.
The moat is not absolute. The 2025 Form 10-K notes channel pressure from internet retailers and big-box outlets, and pet owners may substitute lower-cost human health products in some cases. Still, replacing Zoetis's approved products requires evidence, pharmacovigilance, manufacturing control, and veterinary adoption rather than just lower-cost chemistry.
Decentralization reading
Zoetis's finished medicines are difficult to decentralize safely because dosing, contraindications, adverse-event reporting, supply quality, veterinary supervision, and regulatory approvals are essential parts of the product.
The decentralizable layers sit around the product: open drug-discovery infrastructure, clinic-owned outcome registries, federated parasite-risk data, transparent comparative-effectiveness studies, and cooperative purchasing or generic-access programs once exclusivity and regulatory constraints allow substitution.
Products
Where the moat actually touches users
These pages zoom into the products and services that matter most to each company, the alternatives already nibbling at them, and 2 structured disruption concepts across the current product set.
2 disruption concepts tracked0 documented exceptions
Apoquel
Veterinary dermatology medicine
1 conceptApoquel is Zoetis's oclacitinib-based prescription product family for allergic itch and atopic dermatitis in dogs at least 12 months old.
Simparica Trio
Companion animal parasiticide
1 conceptSimparica Trio is a monthly prescription chewable for dogs that combines protection against heartworm disease, fleas, multiple tick species, roundworms, hookworms, and flea tapeworm risk via flea control.
Technology waves
Strategic lenses
These are the repo's explicit bias terms: the technologies expected to keep making incumbents less inevitable over time.
Paper trail
Visible evidence trail
These sources shaped the scoring and writing. The site is opinionated, but it should not behave like it is improvising facts in a dark room.
Zoetis 2025 Form 10-K
U.S. Securities and Exchange Commission · annual report
Primary filing for 2025 revenue, net income, segment mix, product-category revenue, channel risks, and regulated manufacturing context.
Reviewed 2026-06-27
Zoetis Investor Relations Corporate Overview
Zoetis · investor relations
Company overview describing Zoetis as an animal-health company with medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions across more than 100 countries.
Reviewed 2026-06-27
Zoetis Market Capitalization
CompaniesMarketCap · market data
Market-cap reference for Zoetis, including June 2026 market capitalization and June 26, 2026 end-of-day market-cap comparison.
Reviewed 2026-06-27
Zoetis Statistics and Valuation
StockAnalysis · market data
Market-data source for trailing P/E ratio, market capitalization cross-check, shares outstanding, revenue, net income, and price timestamp.
Reviewed 2026-06-27